Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
11.05
+0.09 (0.82%)
Nov 21, 2024, 10:49 AM EST - Market open

Artiva Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
2.633.494.932--
Revenue Growth (YoY)
-43.11%579.21%146.30%---
Gross Profit
2.633.494.932--
Selling, General & Admin
15.4213.9120.7812.864.432.09
Research & Development
48.1650.2543.9842.4113.851.32
Operating Expenses
63.5964.1664.7655.2718.273.41
Operating Income
-60.99-30.67-59.83-53.27-18.27-3.41
Interest Expense
-----0.2-0.26
Interest & Investment Income
3.762.541.29-00.03
Other Non Operating Income (Expenses)
-3.87-0.41-0.2-18.550.48-0.7
EBT Excluding Unusual Items
-61.1-28.55-58.74-71.83-17.99-4.35
Gain (Loss) on Sale of Investments
-0.1-0.1----
Pretax Income
-61.2-28.65-58.74-71.83-17.99-4.35
Income Tax Expense
0.070.070.05---
Net Income
-61.28-28.72-58.79-71.83-17.99-4.35
Net Income to Common
-61.28-28.72-58.79-71.83-17.99-4.35
Shares Outstanding (Basic)
511111
Shares Outstanding (Diluted)
511111
Shares Change (YoY)
589.85%4.70%11.80%8.60%3.59%-
EPS (Basic)
-11.42-35.78-76.67-104.73-28.49-7.13
EPS (Diluted)
-11.42-35.78-76.67-104.73-28.49-7.13
Free Cash Flow
-52.27-50.69-57.13-17.03-13.83-3.45
Free Cash Flow Per Share
-9.74-63.14-74.51-24.83-21.89-5.65
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-2344.68%-91.58%-1213.32%-2660.94%--
Profit Margin
-2355.86%-85.75%-1192.21%-3587.66%--
Free Cash Flow Margin
-2009.65%-151.34%-1158.55%-850.55%--
EBITDA
-58.57-28.41-58.67-53.02-18.2-3.4
EBITDA Margin
--84.81%----
D&A For EBITDA
2.412.271.160.250.070.01
EBIT
-60.99-30.67-59.83-53.27-18.27-3.41
EBIT Margin
--91.58%----
Revenue as Reported
2.633.494.93---
Source: S&P Capital IQ. Standard template. Financial Sources.